30, and change score equivalent to 0.50, effect sizes (ES).
Results: The sample included 911 RRMS patients (67.3% female, age mean (SD) 36.2 (8.4) years, duration of MS mean (SD) 4.8 (5.2) years). Results showed that the PRIMUS and U-FIS had good internal consistency. Appropriate correlations were observed with comparator instruments and both measures
were able to distinguish between participants based on Expanded Disability Status Scale scores and time since diagnosis. The anchor-based and distribution-based RD estimates were: PRIMUS Activities range = 1.2-2.3, PRIMUS QoL range = 1.0-2.2, and U-FIS range = 2.4-7.0.
Conclusions: The results show that the PRIMUS and U-FIS are valid instruments for use with RRMS patients. The analyses provide preliminary AG-881 manufacturer information on how to interpret scores on the scales. These data will be useful for assessing treatment efficacy and for powering clinical studies.”
“Objective:
To identify the impact of the presence of patent foramen ovale (PFO) in patients undergoing liver find more transplantation.
Methods:
Twenty-seven pre-liver transplant patients who had a PFO (PFO group) were identified and compared with 61 patients without
PFO (NoPFO group). Patients were matched according to age, gender and cause of liver disease. The diagnosis of PFO was made by transthoracic echocardiography prior to liver transplantation. Patient baseline characteristics and complications during the early post-transplant period were analyzed.
Results:
The mean age in the PFO group was 47 +/- 14 (range 18-68) yr and 50 +/- 11 (range SU5402 purchase 12-65) yr in the NoPFO group. The PFO group had a mean model for end-stage liver
disease (MELD) score of 15 +/- 10 whereas in the NoPFO group the MELD score was 19 +/- 10 (p = 0.08). There were non-significant differences in echocardiographic parameters between groups. Duration of mechanical ventilation and the incidence of neurological complications were similar. Thirty-day mortality rate was similar in both groups; only one patient in the NoPFO group died within the first 30 days post-transplantation.
Conclusions:
The presence of PFO in patients with end-stage liver disease undergoing liver transplantation does not appear to affect patient outcomes during the peri-operative period.”
“Previously, we have shown that amphiphilic polymer particles functionalized with both hydrophilic guanidino groups and hydrophobic acyl groups have been shown to immobilize a large amount of lipase with the immobilized lipase retaining high transesterification activity in organic solvent.